Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
2025 Q4 -tulosraportti
71 päivää sitten
7,95 DKK/osake
Viimeisin osinko
4,75%Tuotto/v

Tarjoustasot

DenmarkNasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
62--
869--
2 790--
1 300--
1 300--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q1 -tulosraportti
6.5.
Menneet tapahtumat
Vuosittainen yhtiökokous 2026
26.3.
2025 Q4 -tulosraportti
4.2.
Ylimääräinen yhtiökokous 2025
14.11.2025
2025 Q3 -tulosraportti
5.11.2025
2025 Q2 -tulosraportti
6.8.2025

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 3 t sitten
    ·
    3 t sitten
    ·
    Here we go again. The train is leaving, are you on board? Toot toot lambo lambo
    3 t sitten
    ·
    3 t sitten
    ·
    Hope you are right 🙏🤞👆
  • 3 t sitten
    ·
    3 t sitten
    ·
    NYSE - Nasdaq Real Time Price Novo Nordisk A/S (NVO) USD40.81 DKK258,32 At close: 3:59:59 PM EDT Bernstein's concealed price target of 175 DKK for Novo Nordisk will go down in history as one of the most bizarre misjudgments. It's hard not to wonder if the analysis describes the company – or a parallel reality. The difference is not a nuance, but an expression of a significant cognitive dissonance. Bernstein, you are a laughing stock. Good night.
    2 t sitten
    ·
    2 t sitten
    ·
    I have not read Bernstein's analysis, but how do they arrive at a price of 175, does anyone know this?
  • 3 t sitten · Muokattu
    ·
    3 t sitten · Muokattu
    ·
    Novo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and changes gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors", the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who have nevertheless experienced reduced inflammation and scarring in the liver. Understanding the exact biological process is now very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism 14 April https://www.cell.com/cell-metabolism/abstract/S1550-4131(26)00105-1
    4 t sitten
    ·
    4 t sitten
    ·
    Is the news twice as good if one publishes it twice?
    3 t sitten
    ·
    3 t sitten
    ·
    Agreed 🙏🤞👆
  • 4 t sitten
    ·
    4 t sitten
    ·
    Novo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and alters gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors" the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who nevertheless experienced reduced inflammation and scarring in the liver. That the exact biological process is now understood is very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up for potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism.
  • 5 t sitten
    ·
    5 t sitten
    ·
    Current price 260 ish 💰
    3 t sitten
    ·
    3 t sitten
    ·
    Nej. 258 5.
    3 t sitten
    ·
    3 t sitten
    ·
    Ok but a good figure after all
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti
71 päivää sitten
7,95 DKK/osake
Viimeisin osinko
4,75%Tuotto/v

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 3 t sitten
    ·
    3 t sitten
    ·
    Here we go again. The train is leaving, are you on board? Toot toot lambo lambo
    3 t sitten
    ·
    3 t sitten
    ·
    Hope you are right 🙏🤞👆
  • 3 t sitten
    ·
    3 t sitten
    ·
    NYSE - Nasdaq Real Time Price Novo Nordisk A/S (NVO) USD40.81 DKK258,32 At close: 3:59:59 PM EDT Bernstein's concealed price target of 175 DKK for Novo Nordisk will go down in history as one of the most bizarre misjudgments. It's hard not to wonder if the analysis describes the company – or a parallel reality. The difference is not a nuance, but an expression of a significant cognitive dissonance. Bernstein, you are a laughing stock. Good night.
    2 t sitten
    ·
    2 t sitten
    ·
    I have not read Bernstein's analysis, but how do they arrive at a price of 175, does anyone know this?
  • 3 t sitten · Muokattu
    ·
    3 t sitten · Muokattu
    ·
    Novo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and changes gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors", the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who have nevertheless experienced reduced inflammation and scarring in the liver. Understanding the exact biological process is now very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism 14 April https://www.cell.com/cell-metabolism/abstract/S1550-4131(26)00105-1
    4 t sitten
    ·
    4 t sitten
    ·
    Is the news twice as good if one publishes it twice?
    3 t sitten
    ·
    3 t sitten
    ·
    Agreed 🙏🤞👆
  • 4 t sitten
    ·
    4 t sitten
    ·
    Novo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and alters gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors" the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who nevertheless experienced reduced inflammation and scarring in the liver. That the exact biological process is now understood is very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up for potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism.
  • 5 t sitten
    ·
    5 t sitten
    ·
    Current price 260 ish 💰
    3 t sitten
    ·
    3 t sitten
    ·
    Nej. 258 5.
    3 t sitten
    ·
    3 t sitten
    ·
    Ok but a good figure after all
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

DenmarkNasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
62--
869--
2 790--
1 300--
1 300--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q1 -tulosraportti
6.5.
Menneet tapahtumat
Vuosittainen yhtiökokous 2026
26.3.
2025 Q4 -tulosraportti
4.2.
Ylimääräinen yhtiökokous 2025
14.11.2025
2025 Q3 -tulosraportti
5.11.2025
2025 Q2 -tulosraportti
6.8.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti
71 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q1 -tulosraportti
6.5.
Menneet tapahtumat
Vuosittainen yhtiökokous 2026
26.3.
2025 Q4 -tulosraportti
4.2.
Ylimääräinen yhtiökokous 2025
14.11.2025
2025 Q3 -tulosraportti
5.11.2025
2025 Q2 -tulosraportti
6.8.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

7,95 DKK/osake
Viimeisin osinko
4,75%Tuotto/v

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 3 t sitten
    ·
    3 t sitten
    ·
    Here we go again. The train is leaving, are you on board? Toot toot lambo lambo
    3 t sitten
    ·
    3 t sitten
    ·
    Hope you are right 🙏🤞👆
  • 3 t sitten
    ·
    3 t sitten
    ·
    NYSE - Nasdaq Real Time Price Novo Nordisk A/S (NVO) USD40.81 DKK258,32 At close: 3:59:59 PM EDT Bernstein's concealed price target of 175 DKK for Novo Nordisk will go down in history as one of the most bizarre misjudgments. It's hard not to wonder if the analysis describes the company – or a parallel reality. The difference is not a nuance, but an expression of a significant cognitive dissonance. Bernstein, you are a laughing stock. Good night.
    2 t sitten
    ·
    2 t sitten
    ·
    I have not read Bernstein's analysis, but how do they arrive at a price of 175, does anyone know this?
  • 3 t sitten · Muokattu
    ·
    3 t sitten · Muokattu
    ·
    Novo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and changes gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors", the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who have nevertheless experienced reduced inflammation and scarring in the liver. Understanding the exact biological process is now very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism 14 April https://www.cell.com/cell-metabolism/abstract/S1550-4131(26)00105-1
    4 t sitten
    ·
    4 t sitten
    ·
    Is the news twice as good if one publishes it twice?
    3 t sitten
    ·
    3 t sitten
    ·
    Agreed 🙏🤞👆
  • 4 t sitten
    ·
    4 t sitten
    ·
    Novo Nordisk has presented a significant breakthrough in liver health. A new study published in the journal Cell Metabolism finally provides the answer to why semaglutide, the active ingredient in Ozempic and Wegovy, improves the liver even without the patient achieving significant weight loss. The study was led by the renowned researcher Dr. Daniel Drucker at Sinai Health. The researchers found that the medicine has a direct effect on the liver via a specific cell type called liver sinusoidal endothelial cells (LSEC). Traditionally, it has been assumed that the liver became healthier as a secondary effect of weight loss, but this research shows that the medicine actively intervenes and alters gene expression in these cells so that they send out anti-inflammatory signals. In the original article titled "The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors" the mechanism is described as follows: Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver. Dr. Drucker points out that they have observed patients with minimal weight loss who nevertheless experienced reduced inflammation and scarring in the liver. That the exact biological process is now understood is very important for the way forward in medical treatment. Novo Nordisk stands strong in the fight to get semaglutide approved specifically for the treatment of MASH. It also opens up for potential new treatment forms with lower doses for patients who primarily need liver protection, and gives the company a solid scientific lead over competitors. Source: Gonzalez-Rellan MJ, et al. (2026), published in Cell Metabolism.
  • 5 t sitten
    ·
    5 t sitten
    ·
    Current price 260 ish 💰
    3 t sitten
    ·
    3 t sitten
    ·
    Nej. 258 5.
    3 t sitten
    ·
    3 t sitten
    ·
    Ok but a good figure after all
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

DenmarkNasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
62--
869--
2 790--
1 300--
1 300--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt
© 2026 Nordnet Bank AB.
Nordnet | Alvar Aallon katu 5 C, 3. krs | FI-00100 Helsinki